BELLUS Health Inc.

11.35-0.5100-4.30%Vol 909.24K1Y Perf 277.71%
Aug 11th, 2022 16:00 DELAYED
BID11.25 ASK11.56
Open12.59 Previous Close11.86
Pre-Market- After-Market11.60
 - -  0.25 2.20%
Target Price
16.13 
Analyst Rating
Strong Buy 1.14
Potential %
42.11 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.16
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     48.25
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
86.61 
Earnings Rating
Market Cap1.43B 
Earnings Date
10th Aug 2022
Alpha0.05 Standard Deviation0.23
Beta-0.47 

Today's Price Range

11.3012.69

52W Range

2.9412.65

5 Year PE Ratio Range

-13.00-13.70

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-2.41%
1 Month
17.37%
3 Months
45.33%
6 Months
59.19%
1 Year
277.71%
3 Years
57.64%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BLU11.35-0.5100-4.30
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-437 225.00
-435 850.00
-141 834.00
-
RevenueValueIndustryS&P 500US Markets
11.79K
0.00
-18.01
-49.25
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.17-0.18-5.88
Q01 2022-0.18-0.1327.78
Q04 2021-0.28-0.1835.71
Q03 2021-0.24-0.29-20.83
Q02 2021-0.20-0.23-15.00
Q01 2021-0.15-0.20-33.33
Q04 2020-0.13-0.1023.08
Q03 2020-0.16-0.0943.75
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.17
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume909.24K
Shares Outstanding125.79K
Shares Float106.75M
Trades Count10.64K
Dollar Volume10.77M
Avg. Volume1.20M
Avg. Weekly Volume1.18M
Avg. Monthly Volume1.38M
Avg. Quarterly Volume1.03M

BELLUS Health Inc. (NASDAQ: BLU) stock closed at 11.35 per share at the end of the most recent trading day (a -4.3% change compared to the prior day closing price) with a volume of 909.24K shares and market capitalization of 1.43B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. BELLUS Health Inc. CEO is Roberto Bellini.

The one-year performance of BELLUS Health Inc. stock is 277.71%, while year-to-date (YTD) performance is 40.99%. BLU stock has a five-year performance of %. Its 52-week range is between 2.94 and 12.65, which gives BLU stock a 52-week price range ratio of 86.61%

BELLUS Health Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 3.51, a price-to-sale (PS) ratio of 81 762.60, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.72%, a ROC of -33.91% and a ROE of -34.44%. The company’s profit margin is -%, its EBITDA margin is -435 850.00%, and its revenue ttm is $11.79 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from BELLUS Health Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. BELLUS Health Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BELLUS Health Inc. is Strong Buy (1.14), with a target price of $16.13, which is +42.11% compared to the current price. The earnings rating for BELLUS Health Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BELLUS Health Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BELLUS Health Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.62, ATR14 : 0.73, CCI20 : 135.96, Chaikin Money Flow : 0.04, MACD : 0.65, Money Flow Index : 79.96, ROC : 22.04, RSI : 61.01, STOCH (14,3) : 63.98, STOCH RSI : 0.37, UO : 51.69, Williams %R : -36.02), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BELLUS Health Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
7 (87.50 %)
7 (87.50 %)
Moderate Buy
1 (14.29 %)
1 (12.50 %)
1 (12.50 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.14
Strong Buy
1.13
Strong Buy
1.13

BELLUS Health Inc.

BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, development of drug candidates for health solutions.

CEO: Roberto Bellini

Telephone: +1 450 680-4525

Address: 275 Armand-Frappier Boulevard, Laval H7V 4A7, QC, CA

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

59%41%

Bearish Bullish

52%48%

TipRanks News for BLU

Tue, 12 Jul 2022 15:15 GMT H.C. Wainwright Believes BELLUS Health (BLU) Wont Stop Here

- TipRanks. All rights reserved.

Sat, 04 Jun 2022 09:02 GMT Analysts Are Bullish on Top Healthcare Stocks: BELLUS Health (BLU), Immutep Ltd (PRRUF)

- TipRanks. All rights reserved.

Sun, 27 Feb 2022 10:51 GMT BELLUS Health (BLU) Receives a Buy from RBC Capital

- TipRanks. All rights reserved.

Sun, 06 Feb 2022 14:06 GMT BELLUS Health (BLU) Receives a Buy from BTIG

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 01:56 GMT BELLUS Health (BLU) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits